This page shows you your search results in order of relevance. This is page number 14.
Order by Relevance | Date
Total 969764 results found since Jan 2013.
Worldwide Prevalence of Familial Multiple Sclerosis: A Systematic Review and Meta-Analysis
Conclusion We detected significant heterogeneity from Hungary to Saskatchewan for FMS prevalence that was not latitude and ethnicity dependent. This highlighted the accumulation effects of genetic and environment on FMS prevalence. Pooled prevalence of FMS in MS population was calculated 12.6% by random effect in the world.
Source: Multiple Sclerosis and Related Disorders - December 24, 2017 Category: Neurology Source Type: research
Adult brain volume in multiple sclerosis: The impact of paediatric onset
Conclusion Our data support the previous findings that POMS patients have reduced brain and deep grey matter volume, particularly thalamic volume, compared with sex- and age-matched AOMS patients and healthy controls. These findings appear to be independent of disease duration and other clinical features.
Source: Multiple Sclerosis and Related Disorders - March 7, 2018 Category: Neurology Source Type: research
A cross-sectional study on the relationship between cardiorespiratory fitness, disease severity and walking speed in persons with Multiple Sclerosis
Conclusion: The present study shows that 1) an increase of 1 EDSS point is associated with a decrease of 1.88 mL•Kg−1•min−1 when adjusted for time since diagnosis, gender, age and MS type, 2) cardiorespiratory fitness and walking speed was significantly related but only minimally affected by MS type, and 3) hypertension is associated with a lower cardiorespiratory fitness level.
Source: Multiple Sclerosis and Related Disorders - January 12, 2019 Category: Neurology Source Type: research
Validation of 0–10 MS symptom scores in the Australian multiple sclerosis longitudinal study
ConclusionThe six assessed symptoms of the MSSymS performed equally well compared to validated comparison measures in terms of concurrent and predictive validity, temporal stability and responsiveness.
Source: Multiple Sclerosis and Related Disorders - December 27, 2019 Category: Neurology Source Type: research
Similar autobiographical memory impairment in long-term secondary progressive multiple sclerosis and Alzheimer's disease
Conclusion:
Our neuropsychological findings suggest that episodic autobiographical memory is affected in long-term patients with SPMS, possibly due to neurodegenerative processes in functional relevant brain regions.
Source: Multiple Sclerosis - February 6, 2013 Category: Neurology Authors: Muller, S., Saur, R., Greve, B., Melms, A., Hautzinger, M., Fallgatter, A., Leyhe, T. Tags: Research Papers Source Type: research
Increase in the prevalence of multiple sclerosis over a 17-year period in Osona, Catalonia, Spain
This study aimed to probe a possible increase in the prevalence of multiple sclerosis (MS) in Osona over the past 17 years. This was a cross-sectional study including MS-confirmed cases from several sources of information. Crude and adjusted prevalence rates were obtained. One hundred and twenty patients fulfilled the study criteria. The crude prevalence of MS was 79.9 (95% CI: 66.3–95.6) per 100,000 inhabitants and 91.2 (95% CI: 75.5–109.2) per 100,000 among Spanish born individuals. The prevalence of multiple sclerosis cases in Osona has increased over the past 17 years to being one of the highest reported in Spain.
Source: Multiple Sclerosis - February 6, 2013 Category: Neurology Authors: Otero-Romero, S., Roura, P., Sola, J., Altimiras, J., Sastre-Garriga, J., Nos, C., Vaque, J., Montalban, X., Bufill, E. Tags: Short Reports Source Type: research
Long-Term Safety of Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from Phase 3 FREEDOMS II Extension Study (P01.165)
CONCLUSIONS: The long-term safety results of FREEDOMS II extension study were generally consistent with previous fingolimod studies. Switching therapy from placebo to fingolimod after 24 months identified no unexpected safety concerns.Supported by: Novartis Pharma AG, Basel, Switzerland.Disclosure: Dr. Vollmer has received personal compensation for activities with Genzyme Corporation, Acorda Therapeutics, Accelerated Cure Projects for MS, Bristol-Myers Squibb Company, Teva Neuroscience, Biogen Idec, Novartis, and Hoffman-LaRoche. Dr. Vollmer has received research support from Teva Neuroscience, Genzyme Corporation, Ono Pha...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Vollmer, T., Jeffery, D., Goodin, D., Kappos, L., Lublin, F., Radue, E.-W., Rammohan, K., Reder, A., Agius, M., Stites, T., Li, B., Cappiello, L., von Rosenstiel, P., Calabresi, P. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research
Safety, Tolerability and Patient Evaluation of Peginterferon beta-1a Administered Via a Single-Use Autoinjector in Relapsing Multiple Sclerosis: Data from the Phase 3 ATTAIN Study (P01.167)
CONCLUSIONS: Results will help to establish the safety and tolerability profiles of peginterferon beta-1a administered via autoinjector in MS patients, and evaluate patient perceptions of the injection process using the autoinjector.Supported by: Biogen Idec Inc.Disclosure: Dr. Calabresi has received personal compensation for activities with Biogen Idec, Teva Neuroscience, Genzyme Corporation, Vaccinex, Vertex, and Novartis. Dr. Calabresi has received research support from the National Institutes of Health, the National Multiple Sclerosis Society, Nancy Davis Foundation, Biogen Idec, Vertex, Genentech, Inc., Abbott, and Ba...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Calabresi, P., Liu, S., Seddighzadeh, A., Sperling, B., Hung, S., Deykin, A. Tags: P01 Multiple Sclerosis: Treatment Safety Source Type: research
Does First Year MRI and Clinical Activity Correlate with Long Term Clinical Response to Glatiramer Acetate in Multiple Sclerosis Patients? (P01.194)
CONCLUSIONS: Patients on GA after one to two years harbor new brain MRI T1Gd(+) and T2H lesions, which decline over the third year. The significance of new and enhancing MRI lesions and their predictive value over 5 years of follow up will be presented.Supported by: Teva.Disclosure: Dr. Karmon has nothing to disclose. Dr. Ramanathan has received personal compensation for activities with Serono Inc., Biogen Idec, Allergan, Inc., Netezza, Pfizer, Novartis, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation and the National Institutes of Health as a consultant. Dr. Ramanathanhas re...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Karmon, Y., Ramanathan, M., Weinstock-Guttman, B. Tags: P01 Multiple Sclerosis: MS Treatments Source Type: research
Parity Associated with Long-Term Disease Progression in Women with Multiple Sclerosis (P02.130)
CONCLUSIONS: Our results indicate that parous women take a longer time to reach EDSS 6, compared to nulliparous women, suggesting a long term parity benefit. Further studies are necessary to clearly confirm this data as disease specifics may influence a patient to become or not pregnant.Disclosure: Dr. Teter has nothing to disclose. Dr. Kavak has nothing to disclose. Dr. Kolb has nothing to disclose. Dr. Zakalik has nothing to disclose. Dr. Weinstock-Guttman has received personal compensation for activities with Acorda Therapeutics, Biogen Idec, Serono Inc., Novartis, Pfizer, Inc., Teva Neuroscience and Genentech, Inc. as ...
Source: Neurology - February 14, 2013 Category: Neurology Authors: Teter, B., Kavak, K., Kolb, C., Zakalik, K., Weinstock-Guttman, B. Tags: P02 Multiple Sclerosis: Pregnancy and Hormonal Influences Source Type: research
MS Inc.: The Myth About Multiple Sclerosis and Mercury
Mention of one of the original scams in a recent comment brought the topic, flooding with unexpected emotion, to me this week. I’ve touched on this subject before under the heading of MS Quackery and it’s time it was put to bed.
Mercury poisoning was first “linked” to multiple sclerosis in the surrounds of Minamata Bay, Japan in the 1950’s. To be fair, looking at the symptoms of this massive episode which now takes on the name of the bay – Minamata Disease, you can see why one might think of MS:
Symptoms include ataxia, numbness in the hands and feet, general muscle weakness, narrowing of the field of vision ...
Source: Life with MS - February 27, 2013 Category: Other Conditions Authors: admin Tags: myths about ms mercury and ms myths about multiple sclerosis Source Type: blogs
'Clinically definite benign multiple sclerosis', an unwarranted conceptual hodgepodge: evidence from a 30-year observational study
Conclusions:
This 30-year observational study, which is one of the largest published series, indicates that favourable 10-year disability scores of DSS 2 or 3 fail to ensure a long-term benign course of multiple sclerosis. After every decade almost half of the CDBMS were no longer benign. CDBMS, as currently defined, is an unwarranted conceptual hodgepodge. Other criteria using new biomarkers (genetic, biologic or MRI) should be found to detect benign cases of MS.
Source: Multiple Sclerosis - April 17, 2013 Category: Neurology Authors: Leray, E., Coustans, M., Le Page, E., Yaouanq, J., Oger, J., Edan, G. Tags: Research Papers Source Type: research
CXCL13 is a biomarker of inflammation in multiple sclerosis, neuromyelitis optica, and other neurological conditions
CXCL13, a B-cell chemokine, has been proposed as a biomarker in a variety of conditions, some of which can mimic multiple sclerosis and can have very high levels. In this case-control study, cerebrospinal fluid (CSF) CXCL13 was elevated in multiple sclerosis, neuromyelitis optica and other inflammatory neurological controls compared with noninflammatory controls. Levels did not differentiate disease groups. For all subjects taken together, CSF CXCL13 correlated with CSF WBC, oligoclonal band numbers, CSF protein, EDSS, and neurofilament levels. In subgroup analyses, CSF CXCL13 correlated with CSF WBC in neuromyelitis optic...
Source: Multiple Sclerosis - July 29, 2013 Category: Neurology Authors: Alvarez, E., Piccio, L., Mikesell, R. J., Klawiter, E. C., Parks, B. J., Naismith, R. T., Cross, A. H. Tags: Short Reports Source Type: research
A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis
Conclusions
FACETS is effective in reducing fatigue severity and increasing fatigue self-efficacy. However, it is difficult to assess the additional cost in terms of cost-effectiveness (ie, cost per QALY) as improvements in fatigue are not reflected in the QALY outcomes, with no significant differences between FACETS and CLP. The strengths of this trial are its pragmatic nature and high external validity.
Trial registration:
Current Controlled Trials ISRCTN76517470.
Source: Journal of Neurology, Neurosurgery and Psychiatry - September 2, 2013 Category: Neurosurgery Authors: Thomas, S., Thomas, P. W., Kersten, P., Jones, R., Green, C., Nock, A., Slingsby, V., Smith, A. D., Baker, R., Galvin, K. T., Hillier, C. Tags: Open access, Immunology (including allergy), Multiple sclerosis Source Type: research
Call for Nominations: Barancik Prize for Innovation in Multiple Sclerosis Research
The Barancik Prize for Innovation in Multiple Sclerosis Research recognizes an exceptional scientist or a team of scientists whose work in MS research has demonstrated outstanding innovation and originality. This annual prize, made possible by the generosity of the Charles and Margery Barancik SO Foundation, is $100,000 to be used at the discretion of the recipient. Criteria and Nominations The goal of the prize is to recognize innovation in scientific research in the field of multiple sclerosis. Nominations must be submitted on behalf an individual, or team of individuals, by one or more colleagues or mentors. Self...
Source: ScanGrants feed - September 4, 2013 Category: Research Authors: National Multiple Sclerosis Society/Charles and Margery Barancik SO Foundation Source Type: funding
